Nadja Uhlig

Nadja Uhlig

Auto-generated profile, based on publicly available information

Nadja Uhlig

Fraunhofer Institute for Cell Therapy and Immunology, Preclinical Validation, Leipzig, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DLDennis Lapuente
Dennis Lapuente
JFJana Fuchs
Jana Fuchs
JWJonas Willar
Jonas Willar
AAAna Vieira Antão
Ana Vieira Antão
VEValentina Eberlein
Valentina Eberlein
MTMatthias Tenbusch
Matthias Tenbusch
Several effective SARS-CoV-2 vaccines are currently in use, but effective boosters are needed to maintain or increase immunity due to waning responses and the emergence of novel variants. Here we report that intranasal vaccinations with adenovirus 5 and 19a vectored vaccines following a systemic plasmid DNA or mRNA priming result in systemic and mucosal immunity in mice. In contrast to two intramuscular applications of an mRNA vaccine, intranasal boosts with adenoviral vectors induce high levels of mucosal IgA and lung-resident memory T cells (TRM); mucosal neutralization of virus variants of concern is also enhanced. The mRNA prime provokes a comprehensive T cell response consisting of circulating and lung TRM after the boost, while the plasmid DNA prime induces mostly mucosal T cells. Concomitantly, the intranasal boost strategies lead to complete protection against a SARS-CoV-2 infection in mice. Our data thus suggest that mucosal booster immunizations after mRNA priming is a promising approach to establish mucosal immunity in addition to systemic responses.

16 June 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CGChristian Gege
Christian Gege
FBFernando J. Bravo
Fernando J. Bravo
NUNadja Uhlig
Nadja Uhlig
THTimo Hagmaier
Timo Hagmaier
RSRosanne Schmachtenberg
Rosanne Schmachtenberg
GKGerald Kleymann
Gerald Kleymann
More than 50% of the world population is chronically infected with herpesviruses. Herpes simplex virus (HSV) infections are the cause of herpes labialis (cold sores), genital herpes, and sight-impairing keratitis. Less frequently, life-threatening disseminated disease (encephalitis and generalized viremia) can also occur, mainly in immunocompromised patients and newborns. After primary infection, HSV persists for life in a latent state in trigeminal or sacral ganglia and, triggered by diverse stimuli, disease recurs in more than 30% of patients up to several times a year. Current therapy with nucleoside analogs targeting the viral polymerase is somewhat effective but limited by poor exposure in the nervous system, and latent infections are not affected by therapy. Here, we report on an inhibitor of HSV helicase-primase with potent in vitro anti-herpes activity, a different mechanism of action, a low frequency of HSV resistance, and a favorable pharmacokinetic and safety profile. Improved target tissue exposure results in superior efficacy in preventing and treating HSV infection and disease in animal models as compared to standard of care. Therapy of primary HSV infections with drug candidate IM-250 {(S)-2-(2′,5′-difluoro-[1,1′-biphenyl]-4-yl)-N-methyl-N-(4-methyl-5-(S-methylsulfon-imidoyl)thiazol-2-yl)acetamide} not only reduces the duration of disease symptoms or time to healing but also prevents recurrent disease in guinea pigs. Treatment of recurrent infections reduces the frequency of recurrences and viral shedding, and, unlike nucleosidic drugs, IM-250 remains effective for a time after cessation of treatment. Hence, IM-250 has advantages over standard-of-care therapies and represents a promising therapeutic for chronic HSV infection, including nucleoside-resistant HSV.

6 September 2022 in JACS Au
Verified
Journal Article
Open access
TWTatjana Weil
Tatjana Weil
AKAbbna Kirupakaran
Abbna Kirupakaran
MLMy-Hue Le
My-Hue Le
PRPhilipp Rebmann
Philipp Rebmann
JMJoel Mieres-Perez
Joel Mieres-Perez
JMJan Münch
Jan Münch

19 September 2024 in Antiviral Research
Verified
Journal Article
Open access
AHAlexandra Herrmann
Alexandra Herrmann
CGChristian Gege
Christian Gege
CWChristina Wangen
Christina Wangen
SWSabrina Wagner
Sabrina Wagner
MKMelanie Kögler
Melanie Kögler
FHFriedrich Hahn
Friedrich Hahn
Host-directed antivirals (HDAs) represent an attractive treatment option and a strategy for pandemic preparedness, especially due to their potential broad-spectrum antiviral activity and high barrier to resistance development. Particularly, dual-targeting HDAs offer a promising approach for antiviral therapy by simultaneously disrupting multiple pathways essential for viral replication. Izumerogant (IMU-935) targets two host proteins, (i) the retinoic acid receptor-related orphan receptor γ isoform 1 (RORγ1), which modulates cellular cholesterol metabolism, and (ii) the enzyme dihydroorotate dehydrogenase (DHODH), which is involved in de novo pyrimidine synthesis. Here, we synthesized optimized derivatives of izumerogant and characterized their antiviral activity in comparison to a recently described structurally distinct RORγ/DHODH dual inhibitor. Cell culture-based infection models for enveloped and non-enveloped DNA and RNA viruses, as well as a retrovirus, demonstrated high potency and broad-spectrum activity against human viral pathogens for RORγ/DHODH dual inhibitors at nanomolar concentrations. Comparative analyses with equipotent single-target inhibitors in metabolite supplementation approaches revealed that the dual-targeting mode represents the mechanistic basis for the potent antiviral activity. For SARS-CoV-2, an optimized dual inhibitor completely blocked viral replication in human airway epithelial cells at 5 nM and displayed a synergistic drug interaction with the nucleoside analog molnupiravir. In a SARS-CoV-2 mouse model, treatment with a dual inhibitor alone, or in combination with molnupiravir, reduced the viral load by 7- and 58-fold, respectively. Considering the clinical safety, oral bioavailability, and tolerability of izumerogant in a recent Phase I study, izumerogant-like drugs represent potent dual-targeting antiviral HDAs with pronounced broad-spectrum activity for further clinical development.

16 July 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
JWJannik Till Wagner
Jannik Till Wagner
SMSandra M. Müller-Schmucker
Sandra M. Müller-Schmucker
WWWenjun Wang
Wenjun Wang
PAPhilipp Arnold
Philipp Arnold
NUNadja Uhlig
Nadja Uhlig
KÜKlaus Überla
Klaus Überla
Long-acting passive immunization strategies are needed to protect immunosuppressed vulnerable groups from infectious diseases. To further explore this concept for COVID-19, we constructed Adeno-associated viral (AAV) vectors encoding the human variable regions of the SARS-CoV-2 neutralizing antibody, TRES6, fused to murine constant regions. An optimized vector construct was packaged in hepatotropic (AAV8) or myotropic (AAVMYO) AAV capsids and injected intravenously into syngeneic TRIANNI-mice. The highest TRES6 serum concentrations (511 µg/ml) were detected 24 weeks after injection of the myotropic vector particles and mean TRES6 serum concentrations remained above 100 µg/ml for at least one year. Anti-drug antibodies or TRES6-specific T cells were not detectable. After injection of the AAV8 particles, vector mRNA was detected in the liver, while the AAVMYO particles led to high vector mRNA levels in the heart and skeletal muscle. The analysis of the Fc-glycosylation pattern of the TRES6 serum antibodies revealed critical differences between the capsids that coincided with different binding activities to murine Fc-γ-receptors. Concomitantly, the vector-based immune prophylaxis led to protection against SARS-CoV-2 infection in K18-hACE2 mice. High and long-lasting expression levels, absence of anti-drug antibodies and favourable Fc-γ-receptor binding activities warrant further exploration of myotropic AAV vector-based delivery of antibodies and other biologicals.

3 June 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AHAlexandra Herrmann
Alexandra Herrmann
FHFriedrich Hahn
Friedrich Hahn
CWChristina Wangen
Christina Wangen
SWSabrina Wagner
Sabrina Wagner
ACArne Cordsmeier
Arne Cordsmeier
CGChristian Gege
Christian Gege